328 related articles for article (PubMed ID: 27566557)
21. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
22. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
[TBL] [Abstract][Full Text] [Related]
23. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
24. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
25. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS; Smeland S; Whelan JS; Marina N; Jovic G; Hook JM; Krailo MD; Gebhardt M; Pápai Z; Meyer J; Nadel H; Randall RL; Deffenbaugh C; Nagarajan R; Brennan B; Letson GD; Teot LA; Goorin A; Baumhoer D; Kager L; Werner M; Lau CC; Sundby Hall K; Gelderblom H; Meyers P; Gorlick R; Windhager R; Helmke K; Eriksson M; Hoogerbrugge PM; Schomberg P; Tunn PU; Kühne T; Jürgens H; van den Berg H; Böhling T; Picton S; Renard M; Reichardt P; Gerss J; Butterfass-Bahloul T; Morris C; Hogendoorn PC; Seddon B; Calaminus G; Michelagnoli M; Dhooge C; Sydes MR; Bernstein M;
J Clin Oncol; 2015 Jul; 33(20):2279-87. PubMed ID: 26033801
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
Uchida A; Myoui A; Araki N; Yoshikawa H; Shinto Y; Ueda T
Cancer; 1997 Jan; 79(2):411-5. PubMed ID: 9010116
[TBL] [Abstract][Full Text] [Related]
28. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
Lin F; Wang Q; Yu W; Tang L; Zheng S; Sun Y; Shen Z; Yao Y; Dong Y
Asia Pac J Clin Oncol; 2011 Sep; 7(3):270-5. PubMed ID: 21884438
[TBL] [Abstract][Full Text] [Related]
29. Treatment of large osteosarcoma in children: new approach.
Kobys VL; Konovalenko VF; Repinа NV; Golovko TS; Gulak LO; Tarasova TO; Zaharycheva EV; Matyushok OF
Exp Oncol; 2013 Jun; 35(2):105-8. PubMed ID: 23828385
[TBL] [Abstract][Full Text] [Related]
30. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.
Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
Pharmacogenet Genomics; 2014 Oct; 24(10):514-21. PubMed ID: 25098908
[TBL] [Abstract][Full Text] [Related]
31. An update on chemotherapy for osteosarcoma.
Ferrari S; Serra M
Expert Opin Pharmacother; 2015; 16(18):2727-36. PubMed ID: 26512909
[TBL] [Abstract][Full Text] [Related]
32. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
33. Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.
Hattinger CM; Patrizio MP; Luppi S; Magagnoli F; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):299-311. PubMed ID: 30822170
[TBL] [Abstract][Full Text] [Related]
34. Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy.
Yang J; Wang ZG; Cai HQ; Li YC; Xu YL
Asian Pac J Cancer Prev; 2013; 14(8):4595-8. PubMed ID: 24083708
[TBL] [Abstract][Full Text] [Related]
35. Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas.
Wang B; Yao H; Xie X; Yin J; Zou C; Huang G; Shen J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):221-227. PubMed ID: 29808416
[TBL] [Abstract][Full Text] [Related]
36. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
[TBL] [Abstract][Full Text] [Related]
37. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
[TBL] [Abstract][Full Text] [Related]
38. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
Ferrari S; Palmerini E; Staals E; Abate ME; Longhi A; Cesari M; Balladelli A; Pratelli L; Bacci G
J Chemother; 2009 Apr; 21(2):205-10. PubMed ID: 19423475
[TBL] [Abstract][Full Text] [Related]
39. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.
Harris MB; Gieser P; Goorin AM; Ayala A; Shochat SJ; Ferguson WS; Holbrook T; Link MP
J Clin Oncol; 1998 Nov; 16(11):3641-8. PubMed ID: 9817286
[TBL] [Abstract][Full Text] [Related]
40. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
Serra M; Scotlandi K; Reverter-Branchat G; Ferrari S; Manara MC; Benini S; Incaprera M; Bertoni F; Mercuri M; Briccoli A; Bacci G; Picci P
J Clin Oncol; 2003 Feb; 21(3):536-42. PubMed ID: 12560446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]